琥珀酸他舒格替尼价格一览

Introduction: As of now, tasugatinib succinate has not been launched in mainland China, nor has it been included in the Chinese medical insurance directory. The price system and usage specifications of targeted drugs are directly related to the feasibility of treatment options. This article systematically reviews the global pricing status, regional access policies and standardized dosing regimens of tasugatinib succinate, providing a multi-dimensional reference basis for clinical decision-making.

Global pricing status of tasugatinib succinate

The current market of tasugatinib succinate presents an exclusive supply pattern of the original drug, and the price is affected by both patent protection and market strategies. The global pricing of the standard package of 35mg*56 tablets varies significantly, and there is no legal imitation version.

Original drug price

The price of tasugatinib succinate is approximately US$7,131 per box, and the single-day treatment cost is approximately US$127. The price is for reference only and shall be subject to the actual purchase price.

Price of generic drugs

There is currently no generic version of tasugatinib succinate approved for marketing, and the price of its generic version cannot be known.

Domestic drug access status

This drug has not yet passed the marketing license approval of the State Food and Drug Administration, and domestic formal medical channels are not yet open for supply. Information released by the drug regulatory department shows that this variety is in the phase III clinical trial data verification stage.

Special medication channel

Patients who meet specific indications can apply for a licensed import and must provide a clinical demand certificate signed by hospital experts.

Clinical research opportunities

Extended research on tasugatinib succinate may be underway in China, and enrolled patients will receive free drug treatment. The research plan sets up a flexible withdrawal mechanism to allow those with significant curative effects to be transferred to the long-term medication observation group.

Standardized dosing regimen

Based on global multi-center clinical trial data, a stepped dose adjustment system has been established. The implementation of the treatment plan needs to be dynamically optimized based on the patient's body weight, metabolic function and treatment response.

Basic dosing mode

The starting dose is set to 140 mg orally in a single daily dose, and it is recommended to take it on an empty stomach at a fixed period. A baseline liver function test needs to be completed before treatment, and the treatment cycle is based on 21 days as the evaluation point.

Dose adjustment process

When grade 2 adverse reactions occur, the dose is lowered to 105 mg/day for the first time. If symptoms persist, the second phase of adjustment will be entered and the dose will be reduced to 70 mg. For patients with special physiques, the depth of maintenance treatment can be adjusted to 35 mg.

Termination criteria

When grade 4 hematological toxicity or grade 3 non-hematological toxicity occurs, administration should be suspended immediately. If there is no improvement or recurrence after 14 days of symptomatic treatment, the drug treatment program needs to be permanently discontinued.

For intolerable grade 2 or 3 corneal/retinal lesions, the drug needs to be discontinued until the symptoms are reduced to grade 1 or below, and then dose restoration can be considered. If grade 4 lesions occur, dosing must be permanently discontinued.